Skip to main content
Book Chapter

Clinical Trials in IPF: What Are the Best Endpoints?

  • Spagnolo P
  • Cocconcelli E
  • Cottin V
DOI: 10.1007/978-3-319-99975-3_19
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Idiopathic pulmonary fibrosis (IPF), the most common and lethal of all chronic idiopathic interstitial pneumonias, is a disease that is rare and is still regarded as an orphan condition. Indeed, in the last decade more than 3000 patients have been enrolled in...

Cite

CITATION STYLE

APA

Spagnolo, P., Cocconcelli, E., & Cottin, V. (2019). Clinical Trials in IPF: What Are the Best Endpoints? (pp. 433–453). https://doi.org/10.1007/978-3-319-99975-3_19

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free